Article

The pharmacokinetics, pharmacodynamics and pharmacogenetics of Dolutegravir and Cobicistat in the treatment of HIV

2019-01-01

Abstract excerpt

Dolutegravir (DTG), the second-generation Integrase Inhibitor (InSTI) and Cobicistat (COBI), the new pharmacological booster, were approved for the treatment of HIV in 2013-14. DTG changed the landscape of HIV therapy, raising standards for efficacy, safety and genetic barrier. It is now recommended as first line therapy in most major including universal guidelines and is the anchor drug for a number of new simpli...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ff3bed65-a19b-5806-89d1-4f64b2639a60
DOI: 10.17638/03076608

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The pharmacokinetics, pharmacodynamics and pharmacogenetics of Dolutegravir and Cobicistat in the treatment of HIVDOI 10.17638/03076608Read

Dolutegravir for the treatment of HIVSemantic proximity Read

Dolutegravir plus lamivudine for the treatment of HIV-1 infection.Semantic proximity Read

Dolutegravir: an exciting new kid on the block.Semantic proximity Read

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysisSemantic proximity Read

Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review.Semantic proximity Read

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.Semantic proximity Read

Cobicistat: Review of a Pharmacokinetic Enhancer for HIV InfectionSemantic proximity Read

Dolutegravir resistance mutations: lessons from monotherapy studies.Semantic proximity Read

PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests".Semantic proximity Read

British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010.Semantic proximity Read

Investigation of molecular mechanisms regulating drug-drug interactions in antiretroviral therapySemantic proximity Read

Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid InhibitorSemantic proximity Read